{"hands_on_practices": [{"introduction": "To initiate an immune response against an extracellular pathogen, an antigen-presenting cell must first break it down into recognizable pieces. This first practice explores the critical nature of this processing step. By considering a hypothetical scenario where this process goes awry, you can deduce the fundamental requirements for a molecule to be presented on the MHC class II platform and activate CD4+ helper T-cells [@problem_id:2276001].", "problem": "A team of immunologists is studying a rare, hypothetical genetic disorder they have named Lysosomal Hyperactivity Syndrome (LHS). In patients with LHS, macrophages exhibit a specific functional defect: their lysosomal proteases are extraordinarily aggressive. After a macrophage phagocytoses an extracellular bacterium, these hyperactive enzymes degrade all bacterial proteins completely into their individual constituent amino acids. No larger peptide fragments remain.\n\nConsider a macrophage from an individual with LHS that has just phagocytosed an extracellular bacterial pathogen. What is the most direct and immediate consequence of this specific defect on the macrophage's ability to initiate an adaptive immune response?\n\nA. The macrophage would fail to present exogenous antigens via Major Histocompatibility Complex (MHC) class II, impairing the activation of CD4+ helper T-cells.\n\nB. The macrophage would be unable to process and present any antigens, leading to a complete failure of both MHC class I and MHC class II pathways.\n\nC. The macrophage would present single amino acids on its MHC class II molecules, leading to an aberrant and strong activation of CD8+ cytotoxic T-cells.\n\nD. The breakdown of proteins into single amino acids would provide more binding substrates, leading to an enhanced presentation of antigens on MHC class II and a hyper-inflammatory response.\n\nE. The MHC class I pathway would be overstimulated to compensate, leading to the presentation of bacterial antigens to CD8+ cytotoxic T-cells.", "solution": "Exogenous antigen presentation by macrophages proceeds via the endosomal/lysosomal pathway. The essential steps are: uptake of extracellular antigen by phagocytosis, proteolytic processing in acidified endosomes/lysosomes into peptides of sufficient length, loading of these peptides onto MHC class II molecules after invariant chain degradation and CLIP removal (facilitated by HLA-DM), and surface presentation to CD4+ T cells. A necessary condition for MHC class II loading is the presence of peptides of appropriate length and sequence; the MHC class II peptide-binding groove is open-ended and typically accommodates a core of roughly 9 residues within peptides often 13–18 residues long. Single amino acids cannot bind MHC class II.\n\nIn Lysosomal Hyperactivity Syndrome as described, lysosomal proteases degrade all bacterial proteins completely into individual amino acids, leaving no peptide fragments. Therefore, there are no peptides available for loading onto MHC class II in the late endosome/lysosome (MIIC). This directly impairs presentation of exogenous bacterial antigens via MHC class II and thus prevents effective activation of CD4+ helper T cells.\n\nThis defect does not imply a global failure of antigen presentation: the MHC class I pathway primarily presents endogenous cytosolic peptides generated by the proteasome and transported by TAP into the endoplasmic reticulum, a process not directly dependent on lysosomal proteases. There is no mechanism for presenting single amino acids on MHC molecules, and CD8+ T cells recognize peptides on MHC class I, not class II. There is also no compensatory overstimulation of MHC class I for exogenous bacterial antigens in macrophages (cross-presentation is specialized and largely a dendritic cell function).\n\nTherefore, the most direct and immediate consequence is failure of exogenous antigen presentation via MHC class II, impairing activation of CD4+ helper T cells, which corresponds to option A.", "answer": "$$\\boxed{A}$$", "id": "2276001"}, {"introduction": "After foreign proteins are processed into peptides, the next crucial step is loading these fragments onto MHC class II molecules. This loading does not happen in a vacuum; the peptide-binding groove of a new MHC class II molecule is temporarily occupied by a placeholder called the Class II-associated invariant chain peptide (CLIP). This exercise probes the essential function of CLIP and the machinery that exchanges it for a pathogenic peptide, revealing a key quality control checkpoint in the exogenous pathway [@problem_id:2275971].", "problem": "In a healthy individual, Antigen Presenting Cells (APCs) are responsible for initiating an adaptive immune response against extracellular pathogens. They do this by presenting peptide fragments of the pathogen to T helper cells. This process involves the Major Histocompatibility Complex (MHC) class II molecules. During its synthesis, the peptide-binding groove of an MHC class II molecule is temporarily occupied by a placeholder fragment known as the Class II-associated invariant chain peptide (CLIP). In a specialized cellular compartment, CLIP is normally exchanged for a higher-affinity peptide derived from a pathogen that the APC has internalized. The stable MHC-peptide complex is then displayed on the cell surface for recognition by T helper cells.\n\nConsider a hypothetical genetic disorder where a mutation causes the CLIP fragment to bind to the MHC class II peptide-binding groove with a quasi-irreversible, extremely high affinity. What is the most likely and direct consequence of this condition for the activation of T helper cells that are specific for a new extracellular bacterial infection?\n\nA. T helper cell activation would be massively potentiated due to the stable, high-affinity binding of a ligand to the MHC class II molecule.\n\nB. The activation of pathogen-specific T helper cells would be severely impaired.\n\nC. MHC class II molecules would be unable to traffic to the cell surface and would be retained and degraded in the endoplasmic reticulum.\n\nD. The immune system would compensate by presenting the exogenous bacterial peptides on MHC class I molecules, leading to normal T helper cell activation.\n\nE. T helper cells specific for the CLIP peptide would be strongly activated, triggering a widespread autoimmune reaction.", "solution": "First, state the normal pathway for MHC class II antigen presentation that activates pathogen-specific CD4 T helper cells. Newly synthesized MHC class II molecules associate with the invariant chain in the endoplasmic reticulum; the invariant chain blocks the peptide-binding groove, and after proteolysis in the endosomal/lysosomal pathway, the remaining fragment, CLIP, occupies the groove. In the specialized MHC class II compartment, HLA-DM catalyzes the exchange of CLIP for a higher-affinity exogenous peptide derived from internalized pathogens. The stable MHC class II–peptide complex is then transported to the plasma membrane, where it is recognized by T helper cells via their TCRs, enabling their activation (given appropriate costimulation).\n\nNext, analyze the impact of a mutation that makes CLIP bind quasi-irreversibly with extremely high affinity. If CLIP cannot be displaced, HLA-DM-mediated peptide exchange fails, and pathogen-derived peptides cannot load into the MHC class II groove. Consequently, the APC cannot present the relevant exogenous bacterial peptides to CD4 T cells. Although MHC class II associated with invariant chain/CLIP can traffic out of the ER and can reach late endosomal compartments, failure to exchange CLIP prevents formation of the cognate MHC II–pathogen peptide complexes required for TCR recognition. Therefore, pathogen-specific T helper cells will not receive the necessary antigenic signal and will be poorly or not at all activated.\n\nEvaluate the options:\n- A is incorrect because the high-affinity ligand here is CLIP, a self-peptide placeholder, not the pathogen peptide; stable CLIP occupancy blocks antigen presentation rather than potentiating activation.\n- B is correct: without loading of pathogen-derived peptides onto MHC class II, activation of pathogen-specific T helper cells is severely impaired.\n- C is incorrect: invariant chain binding allows MHC class II to exit the ER; trafficking per se is not blocked by high-affinity CLIP, though appropriate peptide loading is.\n- D is incorrect: exogenous antigens presented on MHC class I (cross-presentation) activate CD8 T cells, not CD4 T helper cells; this would not restore normal T helper activation.\n- E is unlikely: CLIP is a self-peptide; central tolerance eliminates or anergizes high-affinity T cells specific for such self components, so widespread CLIP-specific autoimmunity is not expected.\n\nTherefore, the most direct consequence is severe impairment of pathogen-specific T helper cell activation.", "answer": "$$\\boxed{B}$$", "id": "2275971"}, {"introduction": "In a real infection, an antigen-presenting cell internalizes numerous different proteins, creating a mixture of peptides all competing for a limited number of MHC class II molecules. This leads to the phenomenon of immunodominance, where the immune response is focused on only a few of the many possible epitopes. This final, more advanced practice challenges you to build a quantitative model to understand this competition, integrating concepts like processing rate and binding affinity to predict which peptide will be presented most effectively [@problem_id:2276017].", "problem": "An Antigen Presenting Cell (APC) is being studied for its capacity to process and present two different foreign protein antigens, Antigen A and Antigen B, to which it is simultaneously exposed. Both antigens are taken up by the APC and processed into single, unique peptide epitopes, $P_A$ and $P_B$ respectively, within an endosomal compartment known as the Major Histocompatibility Complex (MHC) Class II Compartment (MIIC).\n\nA simplified kinetic model is proposed to describe the competition between these peptides for binding to MHC class II molecules. The model includes the following assumptions:\n\n1.  The APC is in a large external reservoir, so the concentrations of the initial antigens, $[A_0]$ and $[B_0]$, that are being taken up remain constant.\n2.  The generation of peptides $P_A$ and $P_B$ from their parent antigens follows first-order kinetics, with constant production rates given by $v_{prod,A} = k_{proc,A}[A_0]$ and $v_{prod,B} = k_{proc,B}[B_0]$, where $k_{proc,A}$ and $k_{proc,B}$ are the processing rate constants.\n3.  Within the MIIC, the peptides $P_A$ and $P_B$ compete for binding to a fixed total number of available MHC-II molecules. The binding is reversible and at equilibrium is characterized by the dissociation constants $K_{D,A}$ and $K_{D,B}$ for peptides $P_A$ and $P_B$, respectively.\n4.  Peptides that are free within the MIIC (i.e., not bound to an MHC-II molecule) are subject to degradation. This degradation is modeled as a first-order process with the same rate constant, $k_{deg}$, for both $P_A$ and $P_B$.\n5.  The system is allowed to reach a steady state, where the concentrations of all species (free peptides and peptide-MHC-II complexes) within the MIIC are constant over time. The transport of peptide-MHC-II complexes to the cell surface is assumed not to be a rate-limiting step for the establishment of this intra-compartmental steady state.\n\nYour task is to determine the specific ratio of initial antigen concentrations, $[A_0]/[B_0]$, at which the steady-state concentrations of the two different peptide-MHC-II complexes, $[P_A\\text{:}MHC]$ and $[P_B\\text{:}MHC]$, are exactly equal. This ratio represents the critical \"tipping point\" that determines which antigen is immunodominant. Express your answer as a symbolic expression in terms of the processing rate constants ($k_{proc,A}$, $k_{proc,B}$) and dissociation constants ($K_{D,A}$, $K_{D,B}$).", "solution": "Let $P_{A}$ and $P_{B}$ denote the steady-state concentrations of free peptides, $C_{A}=[P_{A}\\text{:}MHC]$ and $C_{B}=[P_{B}\\text{:}MHC]$ the peptide-MHC complexes, $M$ the concentration of free MHC-II, and $M_{t}$ the total MHC-II in the MIIC so that $M_{t}=M+C_{A}+C_{B}$. Binding equilibria are\n$$K_{D,A}=\\frac{MP_{A}}{C_{A}},\\quad K_{D,B}=\\frac{MP_{B}}{C_{B}},$$\nwhich imply\n$$C_{A}=\\frac{MP_{A}}{K_{D,A}},\\quad C_{B}=\\frac{MP_{B}}{K_{D,B}}.$$\nThus the MHC conservation gives\n$$M_{t}=M+\\frac{MP_{A}}{K_{D,A}}+\\frac{MP_{B}}{K_{D,B}}=M\\left(1+\\frac{P_{A}}{K_{D,A}}+\\frac{P_{B}}{K_{D,B}}\\right),$$\nso\n$$M=\\frac{M_{t}}{1+\\frac{P_{A}}{K_{D,A}}+\\frac{P_{B}}{K_{D,B}}},\\quad C_{A}=\\frac{M_{t}\\frac{P_{A}}{K_{D,A}}}{1+\\frac{P_{A}}{K_{D,A}}+\\frac{P_{B}}{K_{D,B}}},\\quad C_{B}=\\frac{M_{t}\\frac{P_{B}}{K_{D,B}}}{1+\\frac{P_{A}}{K_{D,A}}+\\frac{P_{B}}{K_{D,B}}}.$$\n\nThe free-peptide steady states follow from mass balance with first-order degradation and reversible binding:\n$$\\frac{dP_{A}}{dt}=v_{prod,A}-k_{deg}P_{A}-k_{on,A}MP_{A}+k_{off,A}C_{A},\\quad \\frac{dP_{B}}{dt}=v_{prod,B}-k_{deg}P_{B}-k_{on,B}MP_{B}+k_{off,B}C_{B}.$$\nAt binding equilibrium, $k_{on,i}MP_{i}=k_{off,i}C_{i}$ for $i\\in\\{A,B\\}$, so the binding terms cancel and steady state requires\n$$0=v_{prod,A}-k_{deg}P_{A}\\;\\Rightarrow\\;P_{A}=\\frac{v_{prod,A}}{k_{deg}}=\\frac{k_{proc,A}[A_{0}]}{k_{deg}},\\quad 0=v_{prod,B}-k_{deg}P_{B}\\;\\Rightarrow\\;P_{B}=\\frac{v_{prod,B}}{k_{deg}}=\\frac{k_{proc,B}[B_{0}]}{k_{deg}}.$$\n\nThe tipping point satisfies $C_{A}=C_{B}$. Using the expressions above,\n$$\\frac{M_{t}\\frac{P_{A}}{K_{D,A}}}{1+\\frac{P_{A}}{K_{D,A}}+\\frac{P_{B}}{K_{D,B}}}=\\frac{M_{t}\\frac{P_{B}}{K_{D,B}}}{1+\\frac{P_{A}}{K_{D,A}}+\\frac{P_{B}}{K_{D,B}}}\\;\\Rightarrow\\;\\frac{P_{A}}{K_{D,A}}=\\frac{P_{B}}{K_{D,B}}.$$\nSubstituting the steady-state free-peptide concentrations,\n$$\\frac{\\frac{k_{proc,A}[A_{0}]}{k_{deg}}}{K_{D,A}}=\\frac{\\frac{k_{proc,B}[B_{0}]}{k_{deg}}}{K_{D,B}}\\;\\Rightarrow\\;\\frac{k_{proc,A}[A_{0}]}{K_{D,A}}=\\frac{k_{proc,B}[B_{0}]}{K_{D,B}}\\;\\Rightarrow\\;\\frac{[A_{0}]}{[B_{0}]}=\\frac{k_{proc,B}K_{D,A}}{k_{proc,A}K_{D,B}}.$$\nThis ratio is independent of $k_{deg}$ and of the total MHC amount $M_{t}$.", "answer": "$$\\boxed{\\frac{k_{proc,B}K_{D,A}}{k_{proc,A}K_{D,B}}}$$", "id": "2276017"}]}